基于FABP4介导的血管内皮-平滑肌细胞通讯探讨舒脉胶囊干预外周动脉介入后再狭窄的作用机制

术后再狭窄（PRS）是外周动脉病（PAD）介入治疗后面临的主要难题，中药可能是解决一线抗再狭窄药的耐药、副作用问题的新策略。舒脉胶囊在临床用于PAD及PRS的治疗，前期研究表明，舒脉胶囊可抑制PAD-PRS的关键病理过程-动脉硬化与新生内膜增生，全方效力优于拆方。新证据显示脂肪酸结合蛋白4（FABP4）在介入损伤后血管内皮细胞中高异位表达，介导了血管内皮与平滑肌细胞交流通讯。这提示FABP4可能是舒脉胶囊抑制再狭窄的关键靶点。本研究将通过体内实验与体外实验，以髂动脉球囊损伤大鼠模型、血管内皮细胞、血管平滑肌细胞、FABP4为研究对象，从个体、组织、细胞、蛋白、基因水平研究舒脉胶囊抗PAD-PRS的作用机制，诠释舒脉胶囊温补肾阳、益气活血的科学内涵，为舒脉胶囊进一步的基础研究及临床应用奠定基础。

Postoperative restenosis (PRS) is the main challenge after interventional treatment of peripheral arterial disease (PAD). Chinese medicine may be a new strategy to solve the drug resistance and side effects of mainstream anti-restenosis drugs. The curative effect of Shumai Capsule in the clinical treatment of PAD and PRS is exact. Preliminary studies have shown that Shumai Capsule can inhibit the process of atherosclerosis and neointimal hyperplasia which is the key pathological process of PAD-PRS,and the different two medicine group of shumai capsule have a opposite effect, but combined with synergies.New evidence shows that FABP4 is highly ectopic expressed in vascular endothelial cells after injury and mediates the interaction between vascular endothelial cells and smooth muscle cells. This suggests that FABP4, which mediates communication between vascular endothelium and smooth muscle cells, may be a key target for Shumai capsule to play an important role in anti-restenosis. In this study, in vivo experiments and in vitro experiments were carried out in animal models of Iliac Artery Balloon Injury, vascular endothelial cells, vascular smooth muscle cells and FABP4, from animal, tissue, cell, protein and gene levels.The purpose is to study the mechanism of Shumai capsule against PAD-PRS and to interpret the scientific connotation of Shumai Capsule with warming yang, invigorating qi and promoting blood circulation, and lay the foundation for further basic research and clinical application of Shumai capsule.